Contraception and hyperandrogenism. Clinical effects of a drug containing chlormadinone acetate


Cite item

Full Text

Abstract

The article is devoted to the importance of means of hormonal contraception as a method alternative to abortion, that can aid in preserving the reproductive health of women. The advantages, the main effects and the effectiveness of hormonal contraception and in particular drugs containing chlormadinone acetate (HMA), in patients with irregular menstrual symptoms and hyperandrogenism are discussed as well. The data comes from the study, which allows to regard HMA-containing COCs not only as an effective contraceptive agent with a low percentage of side effects, but a compound having a non-contraceptive effects in the form of a therapeutic effect on acne vulgaris, seborrhea, and other manifestations of hyperandrogenism.

About the authors

V N Prilepskaya

Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation

Email: VPrilepskaya@mail.ru
д-р мед. наук, проф., зам. дир. по науч. работе, рук. научно-поликлинического отд-ния ФГБУ НЦАГиП им. акад. В.И.Кулакова 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4

E A Mezhevitinova

Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation

д-р мед. наук, вед. науч. сотр. поликлинического отд-ния ФГБУ НЦАГиП им. акад. В.И.Кулакова 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4

A A Kuzemin

Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation

канд. мед. наук, рук. стационара дневного пребывания ФГБУ НЦАГиП им. акад. В.И.Кулакова 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4

References

  1. Репродуктивное здоровье. Сборник статистических данных Минздрава России, 2013; с. 10-1.
  2. Альбанова В.И., Забненкова О.В. Угри. Учебное пособие для врачей. М., 2014.
  3. Jemes 2002. The Cochrane Library. Review 2012.
  4. Polli 2001. The Cochrane Library. Review 2012.
  5. Boyle J et al. Polycystic ovary syndrome An update. 2012; 41 (10): 752-6.
  6. Seaman 2003. The Cochrane Library. Review 2012.
  7. O’Connell 2008. The Cochrane Library, 2009. Issue 3.
  8. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29-38.
  9. Georg A.K. Schramma, Guido Schrahb. The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women. Contraception 2003; 67 (4): 305-12.
  10. Caruso S, Rugolo S, Agnello C et al. Quality of sexual life in hyperandrogenic women treated with an oral contraceptive containing chlormadinone acetate. J Sex Med 2009; 6 (12): 3376-84.
  11. Демографический понятийный словарь. Население России. 20-й ежегодный демографический доклад. Под ред. А.Г.Вишневского. М., 2012.
  12. Блак М., Макай М. и др. Кожные болезни в акушерско - гинекологической практике. Под ред. В.Н.Прилепской, Е.В.Липовой. 2008.
  13. Arowojolu A.O, Gallo M.F, Lopez L.M, Grimes D.A. Combined oral contraceptive pills for treatment of acne. The Cochrane Library, 2012.
  14. Hadji P, Biskup J, Boekhoff J et al. Evaluation of efficacy, safety and effects on symptoms of androgenization of a generic oral contraceptive containing chlormadinone acetate 2 mg/ethinylestradiol 0,03 mg. Contraception 2012; 86 (4): 359-65.
  15. Prilepskaya V.N, Serov V.N, Zharov E.V et al. Golubev, Effects of aphasicoral contraceptive сontaining desogestre lonfacial seborrhea and acne. Contraception 2003; 68: 239-45.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).